DK0441917T3 - Antiviralt kermesbær-protein - monoklonalt antistofkonjugater - Google Patents

Antiviralt kermesbær-protein - monoklonalt antistofkonjugater

Info

Publication number
DK0441917T3
DK0441917T3 DK90911551.1T DK90911551T DK0441917T3 DK 0441917 T3 DK0441917 T3 DK 0441917T3 DK 90911551 T DK90911551 T DK 90911551T DK 0441917 T3 DK0441917 T3 DK 0441917T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibody
protein
antibody conjugates
turmeric
antiviral
Prior art date
Application number
DK90911551.1T
Other languages
Danish (da)
English (en)
Inventor
Fatih M Uckun
Joyce Mintzer Zarling
Original Assignee
Oncogen
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen, Univ Minnesota filed Critical Oncogen
Application granted granted Critical
Publication of DK0441917T3 publication Critical patent/DK0441917T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK90911551.1T 1989-07-25 1990-07-12 Antiviralt kermesbær-protein - monoklonalt antistofkonjugater DK0441917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (1)

Publication Number Publication Date
DK0441917T3 true DK0441917T3 (da) 1996-09-16

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911551.1T DK0441917T3 (da) 1989-07-25 1990-07-12 Antiviralt kermesbær-protein - monoklonalt antistofkonjugater

Country Status (17)

Country Link
EP (1) EP0441917B1 (ko)
JP (1) JP3109678B2 (ko)
KR (1) KR920700698A (ko)
AT (1) ATE137410T1 (ko)
AU (1) AU631674B2 (ko)
CA (1) CA2037900C (ko)
DE (1) DE69026812T2 (ko)
DK (1) DK0441917T3 (ko)
ES (1) ES2087158T3 (ko)
FI (1) FI911447A0 (ko)
GR (1) GR1002180B (ko)
IE (1) IE74143B1 (ko)
IL (1) IL95134A (ko)
NO (1) NO911174L (ko)
NZ (1) NZ234607A (ko)
PT (1) PT94789B (ko)
WO (1) WO1991001145A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (ko) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物

Also Published As

Publication number Publication date
AU6140590A (en) 1991-02-22
CA2037900A1 (en) 1991-01-26
ATE137410T1 (de) 1996-05-15
PT94789A (pt) 1991-03-20
AU631674B2 (en) 1992-12-03
EP0441917B1 (en) 1996-05-01
JP3109678B2 (ja) 2000-11-20
PT94789B (pt) 1997-04-30
NO911174D0 (no) 1991-03-22
GR1002180B (en) 1996-03-11
FI911447A0 (fi) 1991-03-25
CA2037900C (en) 1999-11-16
ES2087158T3 (es) 1996-07-16
GR900100550A (el) 1991-12-10
WO1991001145A1 (en) 1991-02-07
IE902593A1 (en) 1991-02-27
KR920700698A (ko) 1992-08-10
DE69026812T2 (de) 1996-11-28
NZ234607A (en) 1992-10-28
JPH04502625A (ja) 1992-05-14
DE69026812D1 (de) 1996-06-05
EP0441917A1 (en) 1991-08-21
IL95134A (en) 1996-01-31
IL95134A0 (en) 1991-06-10
NO911174L (no) 1991-05-24
IE74143B1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DK228486D0 (da) Retrovirale polypeptider med tilknytning til human celletransformation
DK97987D0 (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
ES2174837T3 (es) Conjugados de saponina-antigeno y su utilizacion.
SE8600998D0 (sv) Parenterala fenytoinpreparat
DK399489D0 (da) Straek- og varmekrympbar polyaetylenfolie
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
DE3667996D1 (de) Farbige siliconmassen.
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
DK0441917T3 (da) Antiviralt kermesbær-protein - monoklonalt antistofkonjugater
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
ATE71149T1 (de) Monoklonale antikoerper.
ATE141415T1 (de) Konjugate von antikörpern mit variablen domänen
DK528279A (da) Fremgangsmaade til isolering af hepatitis b e antigen eller antistof
DK314886A (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
ES2119778T3 (es) Particulas en marcaje por radionucleidos utilizadas en sinovectomia por radiacion.
GR890100219A (el) Ανθρωπινα μονοκλωνικα αντισωματα που ειδικα αναγνωριζουν κυτταραιου λυσσας κυτταρα που παραγουν τα ιδια, διαμορφωσεις που περιε χουν τα ιδια και παραγωγη ολων αυτων.
DE69122612D1 (de) Interleukin-4-bindeprotein-gamma
ES2155436T3 (es) Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.
ES1015772Y (es) Perfeccionamientos en piezas para union de colgantes.
SE8704876D0 (sv) Civilisationens arme i sverige och hela verlden
SU1612486A1 (ru) Гидродинамические щитки фюзеляжа гидросамолета
DK158948C (da) Indolderivater samt anvendelsen heraf ved fremstilling af indol-carrier-konjugater eller affinitetsmatrixer
NO922878L (no) Noeytralisering og/eller adcc-formidlende monoklonalt hiv-antistoff